Cargando…

Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice?

Detalles Bibliográficos
Autores principales:	Mastorino, Luca, Roccuzzo, Gabriele, Dapavo, Paolo, Siliquini, Niccolò, Avallone, Gianluca, Rubatto, Marco, Quaglino, Pietro, Ribero, Simone
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540258/ https://www.ncbi.nlm.nih.gov/pubmed/35796147 http://dx.doi.org/10.1111/dth.15697

Ejemplares similares

Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population
por: Mastorino, Luca, et al.
Publicado: (2022)

Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study
por: Avallone, Gianluca, et al.
Publicado: (2023)

Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
por: Mastorino, Luca, et al.
Publicado: (2022)

Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study
por: REPETTO, Federica, et al.
Publicado: (2023)

Risankizumab shows high efficacy and maintenance in improvement of response until week 52
por: Mastorino, Luca, et al.
Publicado: (2022)

Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real‐life study
por: Mastorino, Luca, et al.
Publicado: (2022)

Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy
por: MASTORINO, Luca, et al.
Publicado: (2022)

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Phenotypic and Dermoscopic Patterns of Familial Melanocytic Lesions: A Pilot Study in a Third-Level Center
por: Roccuzzo, Gabriele, et al.
Publicado: (2023)

Exploring Psoriasis Inflammatory Microenvironment by NanoString Technologies
por: Ricci, Alessia Andrea, et al.
Publicado: (2023)

Association between Primary Cutaneous B-cell Lymphomas and Other Skin Cancers: A Multicentre Cohort Study
por: AVALLONE, Gianluca, et al.
Publicado: (2022)

Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real‐life experience and therapeutic response to other biological drugs
por: Burzi, Lorenza, et al.
Publicado: (2022)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
por: Nepote, Alessandro, et al.
Publicado: (2022)

Immunotherapy in transplanted patients: A special population that can no longer be ignored
por: Rubatto, Marco, et al.
Publicado: (2021)

Sézary Syndrome: Different Erythroderma Morphological Features with Proposal for a Clinical Score System
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Time to next treatment and safety assessment in cutaneous‐T‐cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

The Skin Microbiome and Its Role in Psoriasis: A Review
por: Celoria, Valentina, et al.
Publicado: (2023)

Primary cutaneous lymphoma patients seen at a referral dermatological centre in 1 year: A single‐centre observational retrospective cohort study of the diagnoses and staging, comorbidities and associated symptoms, treatment performed and clinical course
por: Macagno, N., et al.
Publicado: (2022)

Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
por: Rubatto, Marco, et al.
Publicado: (2021)

Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study
por: Gullo, Giulia, et al.
Publicado: (2022)

Addendum: Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
por: Rubatto, Marco, et al.
Publicado: (2022)

Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer
por: Rubatto, Marco, et al.
Publicado: (2023)

Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real‐life study
por: Mastorino, Luca, et al.
Publicado: (2021)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
por: Ribero, Simone, et al.
Publicado: (2019)

Compositional Alteration of Gut Microbiota in Psoriasis Treated with IL-23 and IL-17 Inhibitors
por: Huang, Yu-Huei, et al.
Publicado: (2023)

Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials
por: Amabile, Simone, et al.
Publicado: (2021)

Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives
por: Roccuzzo, Gabriele, et al.
Publicado: (2021)

The role of IL‐23 and the use of IL‐23 inhibitors in psoriatic arthritis
por: Fragoulis, George E., et al.
Publicado: (2022)

Alopecia areata after COVID-19 vaccination
por: Gallo, Giuseppe, et al.
Publicado: (2022)

Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series
por: REPETTO, Federica, et al.
Publicado: (2022)

The Use of IL-17 and IL-23 Inhibitors in Swedish Clinical Practice: A Register-Based Analysis
por: Norlin, Jenny M, et al.
Publicado: (2023)

Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications
por: Tonella, Luca, et al.
Publicado: (2021)

Comment on: Drug Survival of IL‑12/23, IL‑17 and IL‑23 Inhibitors for Psoriasis Treatment: A Retrospective Multi‑Country, Multicentric Cohort Study
por: Borg, Emma, et al.
Publicado: (2021)

Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?
por: Gialouri, Chrysoula G., et al.
Publicado: (2022)

An Analysis of IL-10, IL-17A, IL-17RA, IL-23A and IL-23R Expression and Their Correlation with Clinical Course in Patients with Psoriasis
por: Kutwin, Magdalena, et al.
Publicado: (2021)

Treatment of Advanced Metastatic Melanoma
por: Quaglino, Pietro, et al.
Publicado: (2021)

Regulatory effects of C5a on IL-17A, IL-17F, and IL-23
por: Grailer, Jamison J., et al.
Publicado: (2013)

Therapeutic potential of targeting IL-17 and IL-23 in sepsis
por: Bosmann, Markus, et al.
Publicado: (2012)

The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis
por: Tsukazaki, Hiroyuki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_edjpntlv8nnmem4dcndr2hpcap